Your browser doesn't support javascript.
loading
Pharmacologic modulation of intracellular Na+ concentration with ranolazine impacts inflammatory response in humans and mice.
Lenz, Max; Salzmann, Manuel; Ciotu, Cosmin I; Kaun, Christoph; Krychtiuk, Konstantin A; Rehberger Likozar, Andreja; Sebestjen, Miran; Goederle, Laura; Rauscher, Sabine; Krivaja, Zoriza; Binder, Christoph J; Huber, Kurt; Hengstenberg, Christian; Podesser, Bruno K; Fischer, Michael J M; Wojta, Johann; Hohensinner, Philipp J; Speidl, Walter S.
Afiliación
  • Lenz M; Department of Internal Medicine II - Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria.
  • Salzmann M; Ludwig Boltzmann Institute for Cardiovascular Research, A-1090 Vienna, Austria.
  • Ciotu CI; Department of Internal Medicine II - Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria.
  • Kaun C; Ludwig Boltzmann Institute for Cardiovascular Research, A-1090 Vienna, Austria.
  • Krychtiuk KA; Center of Physiology and Pharmacology, Medical University of Vienna, 1090 Vienna, Austria.
  • Rehberger Likozar A; Department of Internal Medicine II - Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria.
  • Sebestjen M; Department of Internal Medicine II - Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria.
  • Goederle L; Department of Vascular Disease, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.
  • Rauscher S; Department of Vascular Disease, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.
  • Krivaja Z; Department of Cardiology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.
  • Binder CJ; Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.
  • Huber K; Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria.
  • Hengstenberg C; Core Facility Imaging, Medical University of Vienna, 1090 Vienna, Austria.
  • Podesser BK; Department of Internal Medicine II - Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria.
  • Fischer MJM; Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria.
  • Wojta J; 3rd Medical Department, Cardiology and Intensive Care Medicine, Clinic Ottakring (Wilhelminenhospital), and Sigmund Freud University, Medical Faculty, Vienna, 1020 Austria.
  • Hohensinner PJ; Department of Internal Medicine II - Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria.
  • Speidl WS; Ludwig Boltzmann Institute for Cardiovascular Research, A-1090 Vienna, Austria.
Proc Natl Acad Sci U S A ; 119(29): e2207020119, 2022 07 19.
Article en En | MEDLINE | ID: mdl-35858345
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Sodio / Enfermedad de la Arteria Coronaria / Proteína C-Reactiva / Fármacos Cardiovasculares / Bloqueadores de los Canales de Sodio / Síndrome Coronario Agudo / Ranolazina Tipo de estudio: Clinical_trials Límite: Animals / Humans Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2022 Tipo del documento: Article País de afiliación: Austria
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Sodio / Enfermedad de la Arteria Coronaria / Proteína C-Reactiva / Fármacos Cardiovasculares / Bloqueadores de los Canales de Sodio / Síndrome Coronario Agudo / Ranolazina Tipo de estudio: Clinical_trials Límite: Animals / Humans Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2022 Tipo del documento: Article País de afiliación: Austria